Nimotuzumab shows an additive effect to inhibit cell growth of ALA-PDT treated oral cancer cells

This publication has 28 references indexed in Scilit:

• Postoperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell carcinoma of the base of tongue
  World Journal of Surgical Oncology, 2015
• Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model
  Oncotarget, 2015
• Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients
  Oral Oncology, 2014
• Adjuvant Intraoperative Photodynamic Therapy in Head and Neck Cancer
  JAMA Otolaryngology–Head & Neck Surgery, 2013
• Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma
  Cell Biochemistry and Biophysics, 2013
• Nimotuzumab and Cetuximab Block Ligand-independent EGF Receptor Signaling Efficiently at Different Concentrations
  Journal of Immunotherapy, 2011
• The role of epidermal growth factor receptor in photodynamic therapy: a review of the literature and proposal for future investigation
  Lasers in Medical Science, 2010
• ALA‐PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells
  Lasers in Surgery and Medicine, 2009
• 5-Aminolevulinic acid-induced protoporphyrin-IX accumulation and associated phototoxicity in macrophages and oral cancer cell lines
  Journal of Photochemistry and Photobiology B: Biology, 2007
• GBAS,a Novel Gene Encoding a Protein with Tyrosine Phosphorylation Sites and a Transmembrane Domain, Is Co-amplified withEGFR
  Genomics, 1998